Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 12.6% - Time to Sell?

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) fell 12.6% on Thursday . The stock traded as low as $12.53 and last traded at $13.10. 803,071 shares traded hands during mid-day trading, a decline of 33% from the average session volume of 1,189,804 shares. The stock had previously closed at $14.98.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research note on Sunday, February 2nd. They set a "hold" rating on the stock.

Tonix Pharmaceuticals Trading Up 10.2 %

The stock has a market capitalization of $23.17 million, a P/E ratio of 0.00 and a beta of 2.07. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The stock's 50 day moving average price is $29.63 and its 200-day moving average price is $26.13.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($23.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($203.00) by $180.00. The business had revenue of $2.82 million for the quarter, compared to analysts' expectations of $2.63 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. As a group, equities research analysts expect that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current year.

Institutional Trading of Tonix Pharmaceuticals

An institutional investor recently bought a new position in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned about 0.12% of Tonix Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 82.26% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.